Canada markets closed

DaVita Inc. (DVA)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
97.44+2.02 (+2.12%)
At close: 04:00PM EDT
97.05 -0.39 (-0.40%)
After hours: 04:26PM EDT
Sign in to post a message.
  • b
    Making money off Crypto regardless of it's volatility is totally possible, so you either invest in crypto now or risk losing more with banking only on fiat currencies. I highly recommend Luis’s expertise
    Contact on T3L3gr&m Luispeterr
  • J
    work here, people are leaving in droves. pay is not competitive to rest of market at many position levels. stockholders are the main point now, not the employees. upset workforce will have trouble down the line. already showing
  • R
    It would be in Davita's best interest to purchase RMTI (Rockwell Medical). Davita just entered into another long-term contract with RMTI involving their dialysate called Citrapure.

    Rockwell has another FDA approved dialysis drug called Triferic.

    TRIFERIC® (ferric pyrophosphate citrate)

    TRIFERIC is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD) It is a much less toxic drug than Iron IV.
    Patients that use it feel better, have fewer adverse side effects and less hospitalizations.

    Presently, it is involved in studies in the USA for "at home infusion".

    In China it is in Phase 3 trials and when approved will be another dialysis drug available for over 600,000 Chinese dialysis patients.

    It is being studied in India for people with iron deficiency as their diets lack iron. This is millions of people.

    RMTI is a leading producer of Citrapure which Davita markets. Rockwell would be a perfect acquisition for Davita. They would own Citrapure and Triferic. Rockwell's price per share has suffered in the past 2 years due to Covid and fuel costs and is now at .34 per share.

    It would not surprise me to see Wang Bang of China or Sun Pharma of India or Baxter of the USA make an offer for Rockwell. Citrapure alone is a 60 million+ per year business and justifies a $5.00 stock price without Triferic priced in.
  • J
    Trying to figure out if I’m gonna max out my employee stock purchase plan. They give employees a 15% discount on share price, up to $25,000 worth. Always concerned about government risk since ESRD makes up a huge portion of Medicaid budget…it’s like having a target on your back. But with population aging and growth in number of ESRD patients, hoping DVA will remain solid, particularly with their international expansion.
  • B
    What's amazing to me on this board is there is no discussion about the former CEO -Kent current trial here. The trial is in it's second week. Hmm, I guess this does not matter on this fairly quiet board.
  • J
    NFTS is the new way of becoming rich. Not everybody knows about this or how to get them. Alessandro Dante is the best. He got me some NFTs for $20,000 today my NFT is worth about $500,000 I don't think I'm selling mine any time soon
  • H
    What does Berkshire and other billion dollar hedge funds see in this company? Either the market is inefficient and can't price this security, or there is something many disagree on. Is it litigation risk? Healthcare reform risk? Company seems to throw off good cash flow. Anyone?
  • d
    Just on CNBC Jim Chanos(sp?) shorting DVA for Years and questions Berkshire being involved - they still have 24%.

    A couple comments. Berkshire doesn't ALWAYS make the best moves. Look at the first time that I know of that they bought a Company with another investor(who is slash n loot) from Brazil with Kraft Heinz. You can see what a mis-step that was.

    And actually it was Warren's 2 new hires that both had bought DVA that they had to file 10% ownership not long after they had started.

    Now DVA is at 24% and I believe have a standstill agreement. Which is why I questioned DVA announced a significant buyback not long ago which would increase Berkshire's % ad if that would cause any issues.

    I am long DVA(common and I had sold some common and bought deep in the money calls that are now up 59%.

    It will be interesting to hear why it is shorted. We already know that all profits come from the little sliver of private pay for Davita and Frenesius.

    Capital intensive but a necessary service. And since to me it has a lot of characteristics of a Utility I have always thought they should have a dividend.

    Let the games begin. I have made decent money trading DVA over Years. Virtually all the common and calls I own are with the House's money.

    I had wanted this to be one of my 4 largest holdings but it just can't seem to get there!

    2 folks with WAY more money and information that I will lever have. Time to grab the popcorn and decide if there is an opportunity to make money here.
    And I have been long BRKB's for a very long time. Although I sold a bunch when their split was announced and shortly after that split.

    Chenos to be on CNBC shortly but I have to leave so I won't see it.
  • A
    any idea why unusually high option trades taking place today & yesterday
  • P
    DVA is trading in extremely oversold territory and and should be bought at these bargain basement price for HUGE gains!!!🤔👌🖖
    — Play the rebound in this global sector leader and best of breed business!💰👍📈💪
  • S
    Still wondering where this will go today? With other words, do you sell today?
  • c
    I like this company for an earnings play, am going long in a few minutes, expecting an earnings beat and positive guidance going forward. Only going to do 100 shares, because I see risks and headwinds going forward that might reduce the likelihood of a serious pop up even on a good earnings report. CVS looks much better as an earnings play, but this one is good enough for me to put 100 shares at risk to the long side.
  • T
    hopefully, DVA stays the way it is now for long term investment. I've had confidence with this company that leading by a few smart guys I knew of in the company. I've did bought 1,000 shares at $46 on June-6-2019 and keep for mine kids' educations in colleagues.
  • S
    Warren buffet holds 20 percent of DVA
  • H
    The real magic here and why Berkshire owns over 1/3 of the company is the disappearing share count. If you look at the last 10 years, the share count was as high as 215 million shares. Today it is approaching 100 million.
  • P
    Berkshire Hathaway (BRK.B +1.4%) (BRK.A +1.4%) discloses a 33% stake in Davita (DVA -0.7%), up from 31.7% in a filing dated Sept. 21, 2020.
  • G
    COVID Risk?

    Is there a risk to DVA business model because of COVID?

    dialysis patients are in tight proximity in dialysis centers with 20-30 other patients for 4 hours per session three (3) days per week. The medical staff work at multiple clinics and could potentially transmit disease. Most clinics are in metropolitan areas. End stage renal disease patients requiring dialysis are mostly over 65 years of age and have underlying medical conditions such as hypertension, diabetes, immunosuppression and are often overweight. Similar profile for those at greatest risk of serious COVID infections.

    The map of dialysis locations nation wide looks a lot like the map of confirmed COVID cases

    What is DaVita doing to protect their fragile patients? What is the rate of COVID positive care givers in dialysis clinics? Does DaVita provide infection rate information to their patients? Do the air handling systems in the dialysis clinics have HEPA filters?
    Learn about the various ways to treat kidney disease and manage care.
    Learn about the various ways to treat kidney disease and manage care.
  • d
    Friday closed about 58, Tuesday shortly after open it's at 52 on no news!

    No news on AMTD or Yahoo atleast.


    I recently sold some trading shares since I have purchased Jan 2021 37.50 already that were up significantly so I was doing the old "stock replacement" strategy.

    I mean a lot of big players can certainly move this around. Question is why. And should us individual Investors be concerned about any issues other than a large holder(s) potentially dumping.
  • J
    Two New Fraud Investigations:

    2020 U.S. Attorney New Jersey Investigation: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with the Corporate Integrity Agreement. The Company is cooperating with the government in this investigation.

    2020 California Department of Insurance Investigation: In April 2020, the California Department of Insurance sent the Company a Investigative Subpoena relating to an investigation being conducted by that office. The subpoena requests information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is cooperating with the California Department of Insurance in this investigation.
  • H
    Repurchased 6,127,556 shares of our common stock at an average cost of $105.52 per share in the three months ended December 31, 2021. Repurchased 13,877,193 shares of our common stock at an average cost of $111.41 per share in the year ended December 31, 2021.